A companion poster to the ASCPT print copy, this visual presentation emphasizes the simulation approach used to evaluate individualized dosing strategies and their economic implications. Results underscore the importance of reducing discontinuation rates to enhance value.

This poster presents a modeling framework linking target product profile characteristics to cost-effectiveness outcomes in early drug development for atopic dermatitis. It highlights how persistence of therapy, more than efficacy metrics, may improve cost utility of new treatments.

This study uses pharmacometric and pharmacoeconomic modeling to explore the cost effectiveness of individualized dosing for a hypothetical new atopic dermatitis drug compared to dupilumab. Simulation scenarios tested the impact of treatment discontinuation rates, efficacy variability, and pricing on cost utility outcomes.